Showing results (2521-2530 of 2,814) with videos related to

Sort By:
Pageof 282
Biorxiv : the Preprint Server for Biology|July 18, 2020
A Platform Incorporating Trimeric Antigens into Self-Assembling Nanoparticles Reveals SARS-CoV-2-Spike Nanoparticles to Elicit Substantially Higher Neutralizing Responses than Spike AloneBaoshan Zhang, Cara W Chao, Yaroslav Tsybovsky, et al.
Molecular Cancer Therapeutics|October 17, 2014
Clinical utility of a blood-based BRAF(V600E) mutation assay in melanomaDavid J Panka, Elizabeth Buchbinder, Anita Giobbie-Hurder, et al.
Science Translational Medicine|January 4, 2019
A saliva-based rapid test to quantify the infectious subclinical malaria parasite reservoirDingyin Tao, Brent McGill, Timothy Hamerly, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 26, 2025
Guidance on the management of asymptomatic blood donors who test positive for BabesiaEvan M Bloch, Jeremy W Jacobs, Edouard Vannier, et al.
The Oncologist|May 30, 2013
Ipilimumab for patients with advanced mucosal melanomaMichael A Postow, Jason J Luke, Mark J Bluth, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 18, 2013
Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortiumA Venkatesan, A R Tunkel, K C Bloch, et al.
Molecular Cancer Therapeutics|October 25, 2019
A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic CancerRyan J Sullivan, Antoine Hollebecque, Keith T Flaherty, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 2016
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumabA M Menzies, D B Johnson, S Ramanujam, et al.
Nature Communications|August 27, 2024
Cryoablation and post-progression immune checkpoint inhibition in metastatic melanoma: a phase II trialMeghan J Mooradian, Florian J Fintelmann, Thomas J LaSalle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2015
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT InhibitionRichard D Carvajal, Donald P Lawrence, Jeffrey S Weber, et al.
Pageof 282